Perrigo Co. Plc (PRGO)
14.92
+0.65
(+4.56%)
USD |
NYSE |
Sep 04, 16:00
14.91
-0.01
(-0.07%)
After-Hours: 20:00
Perrigo Research and Development Expense (Quarterly) : 23.70M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.70M |
| March 31, 2026 | 24.60M |
| December 31, 2025 | 21.80M |
| September 30, 2025 | 24.90M |
| June 30, 2025 | 22.00M |
| March 31, 2025 | 26.70M |
| December 31, 2024 | 27.90M |
| September 30, 2024 | 26.00M |
| June 30, 2024 | 29.40M |
| March 31, 2024 | 29.00M |
| December 31, 2023 | 29.70M |
| September 30, 2023 | 29.60M |
| June 30, 2023 | 32.20M |
| March 31, 2023 | 31.10M |
| December 31, 2022 | 32.60M |
| September 30, 2022 | 29.80M |
| June 30, 2022 | 31.50M |
| March 31, 2022 | 29.30M |
| December 31, 2021 | 30.30M |
| September 30, 2021 | 27.60M |
| June 30, 2021 | 33.00M |
| March 31, 2021 | 31.10M |
| December 31, 2020 | 33.00M |
| September 30, 2020 | 42.60M |
| June 30, 2020 | 30.40M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.90M |
| December 31, 2019 | 59.40M |
| September 30, 2019 | 44.00M |
| June 30, 2019 | 43.90M |
| March 31, 2019 | 40.20M |
| December 31, 2018 | 44.60M |
| September 30, 2018 | 43.70M |
| June 30, 2018 | 91.90M |
| March 31, 2018 | 38.40M |
| December 31, 2017 | 46.90M |
| September 30, 2017 | 38.40M |
| June 30, 2017 | 42.60M |
| March 31, 2017 | 39.80M |
| December 31, 2016 | 41.50M |
| September 30, 2016 | 50.20M |
| June 30, 2016 | 47.00M |
| March 31, 2016 | 45.30M |
| December 31, 2015 | 46.60M |
| September 30, 2015 | 41.60M |
| June 30, 2015 | 62.60M |
| March 31, 2015 | 35.40M |
| June 30, 2014 | 38.00M |
| March 31, 2014 | 44.70M |
| December 31, 2013 | 37.50M |
| September 30, 2013 | 32.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Avadel Pharmaceuticals Plc | 27.01M |
| Jazz Pharmaceuticals Plc | 207.50M |
| GH Research Plc | 12.40M |
| Cosmo NV | -- |
| Viatris, Inc. | 245.20M |